Pull to refresh
Logo
David Risinger

David Risinger

Analyst, Leerink Partners

Appears in 3 stories

Last updated Nov 15, 2026

Stories

Blackstone to fund up to $1.5 billion of Pfizer's monthly obesity drug trials

Money Moves

Covering Pfizer

Pfizer has agreed to let Blackstone Life Sciences pay up to $1.5 billion of the development costs for berobenatide, an experimental weight-loss drug injected once a month. The money covers as many as 10 Phase 3 trials through 2028. Pfizer keeps full control of the program and gives up no ownership of the drug.

Updated 7 days ago

Bristol Myers lung drug succeeds at low dose, misses at high dose

New Capabilities

Called the results 'mixed'

Bristol Myers Squibb's experimental lung disease drug admilparant met its main goal in a Phase 3 trial, but only at the lower of two tested doses. The 60 milligram dose slowed lung function decline in patients with idiopathic pulmonary fibrosis, while the 120 milligram dose fell short of statistical significance.

Updated Oct 29

Vaxcyte's pneumococcal vaccine meets all key trial goals, shares surge

New Capabilities

As of October 2026: Views approval chances as intact despite two misses

Vaxcyte said Monday its experimental pneumococcal vaccine met every primary goal in the first of three late-stage trials. VAX-31, which targets 31 strains of the bacteria behind pneumonia and meningitis, matched Pfizer's Prevnar 20 and Merck's Capvaxive on nearly all shared strains, beat both on three strains only it covers, and sent shares up roughly 50% to push the company's market value past $12 billion.

Updated Oct 7